+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions



General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions



Arzneimittel-Forschung 46(7): 681-686



The effects of TCV-116 ((+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1 H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate, CAS 145040-37-5) on the cardiovascular system and renal function were investigated in rats, guinea pigs, and dogs. TCV-116 at doses of 3 mg/kg (i.d.) and higher markedly increased renal blood flow in anesthetized dogs. TCV-116 at 30 mg/kg (i.d.) had no effect on heart rate, left ventricular systolic pressure, its dp/dtmax, or cardiac output in anesthetized dogs. Furthermore, TCV-116 at 10 and 30 mg/kg (p.o.) had little effect on cardiac output, right atrial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure or respiration in conscious dogs. In isolated guinea pig perfused heart, CV-11974 even at a dose of 0.1 mg/ heart had no effect on cardiac function. In isolated guinea-pig atria, CV-11974, the active metabolite of TCV-116, even at 10(-4) mol/l had no effect on the spontaneous beating rate of the right atria or the contractile force of electrically-paced left atria. No significant effect of TCV-116 on urinary volume or urinary excretion of sodium and potassium was observed in rats (at 30, 100 or 300 mg/kg p.o.). These findings suggest that TCV-116 exerts no any additional pharmacological effects on cardiac and respiratory functions in dogs or on renal function in rats, other than an increase in renal blood flow in anesthetized dogs thought to be due to its inhibitory effect on the renin-angiotensin system.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046157578

Download citation: RISBibTeXText

PMID: 8842337


Related references

General pharmacological properties of the new angiotensin II receptor antagonist (racemic)-1-(Cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl) biphenyl-4-yl) methyl)-1H-benzimidazole-7-carboxylate: Part II: Effect on cardiovascular system and renal functions. Arzneimittel Forschung 46(7): 681-686, 1996

General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties. Arzneimittel-Forschung 46(6): 572-579, 1996

General pharmacological properties of the new angiotensin II receptor antagonist (racemic)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylate. Part I. Effects on central nervous system and other properties. Arzneimittel Forschung 46(6): 572-579, 1996

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). Journal of Pharmacology and Experimental Therapeutics 266(1): 114-120, 1993

Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. Journal of Pharmacology and Experimental Therapeutics 268(3): 1540-1547, 1994

The angiotensin receptor antagonist 2-ethoxy-1-[[2'-(1H- tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV11974) attenuates the tubuloglomerular feedback response during NO synthase blockade in rats. Journal of Pharmacology and Experimental Therapeutics 277(2): 572-577, 1996

Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, -1- ethyl 2-ethoxy-1- bipenyl-4-yl-methyl-1H-benzimidazole-7-carboxylate. Journal of Pharmacology & Experimental Therapeutics 268(3): 1540-1547, 1994

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1 biphenyl-4-yl-1H-benzimidazole-7-carboyxlic acid. Journal of Pharmacology & Experimental Therapeutics 266(1): 114-120, 1993

Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-((5-ethyl-3-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl-1,3,4-thiadiazoline-2-ylidene)aminocarbonyl)-1-cyclopentencarboxylate on experimental cardiac hypertrophy and acute left ventricular failure. Arzneimittel Forschung 47(10): 1099-1103, 1997

The angiotensin receptor antagonist 2-ethoxy-1- biphenyl-4-ylmethyl-1H-benzimidazole-7-carboxylic acid. Journal of Pharmacology & Experimental Therapeutics 277(2): 572-577, 1996

Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1,3,4-thiadiazoline-2-ylidene]aminocarbonyl]-1-cy clopentencarbox ylate on experimental cardiac hypertrophy and acute left ventricular failure. Arzneimittel-Forschung 47(10): 1099-1103, 1997

A non-peptide angiotensin II receptor antagonist: 2-butyl-6-dimethoxymethyl-5-phenyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-imidazo[5,4-b]pyridine. Acta Crystallographica. Section C, Crystal Structure Communications 52: 1019-1022, 1996

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist. Bioorganic and Medicinal Chemistry Letters 21(3): 1036-1040, 2011

Evaluation and improvement of bioavailability of a new angiotensin II receptor antagonist, 2-butyl-1- biphenyl-4-yl methyl-1H-benzimidazole-7-carboxylic acid by making prodrug. International Journal of Pharmaceutics (Amsterdam) 103(1): 1-7, 1994

Histopathological and Ultrastructural Changes in the Juxtaglomerular Apparatus of the Rat Following Administration of Zeneca Zd6888 (2-ethyl-5,6,7,8-tetrahydro-4-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methoxylquinoline), an Angiotensin Ii Antagonist. Toxicologic Pathology 23(1): 7-15, 1995